| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CDKN2B antisense RNA 1 | 0.491 | 0.769 |
|
disease | 0.200 | None | 1.000 | 12 | 23 | 2007 | 2020 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.500 | None | 1.000 | 11 | 21 | 2005 | 2019 | |||||||||
|
cancer susceptibility 16 | 0.780 | 0.308 |
|
disease | 0.200 | None | 1.000 | 11 | 4 | 2007 | 2020 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.140 | None | 1.000 | 9 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.140 | None | 1.000 | 9 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 9 | 11 | 2007 | 2014 | |||||||||
|
cancer susceptibility 19 | 0.769 | 0.423 |
|
disease | 0.100 | None | 1.000 | 8 | 12 | 2007 | 2013 | |||||||||
|
LINC02210-CRHR1 readthrough | 0.570 | 0.692 |
|
disease | 0.100 | None | 1.000 | 7 | 31 | 2009 | 2016 | |||||||||
|
long intergenic non-protein coding RNA 2210 | 0.861 | 0.154 |
|
disease | 0.100 | None | 1.000 | 7 | 5 | 2009 | 2016 | |||||||||
|
colon cancer associated transcript 2 | 0.621 | 0.615 |
|
disease | 0.170 | None | 1.000 | 6 | 1 | 2007 | 2019 | |||||||||
|
prostate cancer associated non-coding RNA 1 | 0.722 | 0.385 |
|
disease | 0.170 | None | 1.000 | 6 | 4 | 2008 | 2019 | |||||||||
|
TSBP1 and BTNL2 antisense RNA 1 | 0.638 | 0.692 |
|
disease | 0.100 | None | 1.000 | 6 | 221 | 2007 | 2014 | |||||||||
|
major histocompatibility complex, class II, DR beta 9 (pseudogene) | 0.682 | 0.654 |
|
disease | 0.100 | None | 1.000 | 6 | 4 | 2008 | 2011 | |||||||||
|
cancer susceptibility 11 | 0.641 | 0.577 |
|
disease | 0.120 | None | 1.000 | 5 | 2 | 2008 | 2019 | |||||||||
|
RTEL1-TNFRSF6B readthrough (NMD candidate) | 0.682 | 0.385 |
|
disease | 0.100 | None | 1.000 | 5 | 3 | 2009 | 2019 | |||||||||
|
colon cancer associated transcript 2 | 0.621 | 0.615 |
|
disease | 0.110 | None | 1.000 | 5 | 2 | 2007 | 2016 | |||||||||
|
IL12A antisense RNA 1 | 0.633 | 0.654 |
|
disease | 0.100 | None | 1.000 | 5 | 25 | 2009 | 2017 | |||||||||
|
TSBP1 and BTNL2 antisense RNA 1 | 0.638 | 0.692 |
|
disease | 0.100 | None | 1.000 | 5 | 27 | 2007 | 2013 | |||||||||
|
major histocompatibility complex, class II, DR beta 9 (pseudogene) | 0.682 | 0.654 |
|
disease | 0.100 | None | 1.000 | 5 | 21 | 2007 | 2019 | |||||||||
|
colorectal cancer associated 1 | 0.780 | 0.154 |
|
disease | 0.130 | None | 1.000 | 5 | 1 | 2008 | 2019 | |||||||||
|
CDKN2B antisense RNA 1 | 0.491 | 0.769 |
|
disease | 0.180 | None | 1.000 | 4 | 4 | 2008 | 2019 | |||||||||
|
CDKN2B antisense RNA 1 | 0.491 | 0.769 |
|
disease | 0.160 | None | 0.917 | 4 | 15 | 2009 | 2019 | |||||||||
|
CDKN2B antisense RNA 1 | 0.491 | 0.769 |
|
phenotype | 0.100 | None | 1.000 | 4 | 116 | 2011 | 2013 | |||||||||
|
MAPT antisense RNA 1 | 0.711 | 0.269 |
|
disease | 0.120 | None | 1.000 | 4 | 32 | 2009 | 2019 | |||||||||
|
ADAMTS9 antisense RNA 2 | 0.656 | 0.462 |
|
disease | 0.100 | None | 1.000 | 4 | 2 | 2008 | 2019 |